Crossmark

The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study

Crossref DOI link: https://doi.org/10.1186/s12933-017-0551-5

Published Online: 2017-05-22

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Younis, Arwa

Eskenazi, Dana

Goldkorn, Ronen

Leor, Jonathan

Naftali-Shani, Nili

Fisman, Enrique Z.

Tenenbaum, Alexander

Goldenberg, Ilan

Klempfner, Robert
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct01604213 at ClinicalTrials.gov

Documents that mention this clinical trial

The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study
https://doi.org/10.1186/s12933-017-0551-5
Funding

Funding for this research was provided by:

Novartis Pharmaceuticals Corporation
License Information

Text and Data Mining valid from 2017-05-22

Version of Record valid from 2017-05-22
More Information

Article History

Received: 22 March 2017

Accepted: 13 May 2017

First Online: 22 May 2017

Document is current

Any future updates will be listed below